CN108348582B - 用于使用胰高血糖素受体拮抗性抗体治疗心力衰竭的方法 - Google Patents
用于使用胰高血糖素受体拮抗性抗体治疗心力衰竭的方法 Download PDFInfo
- Publication number
- CN108348582B CN108348582B CN201680061804.XA CN201680061804A CN108348582B CN 108348582 B CN108348582 B CN 108348582B CN 201680061804 A CN201680061804 A CN 201680061804A CN 108348582 B CN108348582 B CN 108348582B
- Authority
- CN
- China
- Prior art keywords
- ser
- gly
- val
- leu
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214449P | 2015-09-04 | 2015-09-04 | |
| US62/214,449 | 2015-09-04 | ||
| US201562259061P | 2015-11-24 | 2015-11-24 | |
| US62/259,061 | 2015-11-24 | ||
| PCT/US2016/050183 WO2017040986A1 (en) | 2015-09-04 | 2016-09-02 | Methods for treating heart failure using glucagon receptor antagonistic antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108348582A CN108348582A (zh) | 2018-07-31 |
| CN108348582B true CN108348582B (zh) | 2023-04-14 |
Family
ID=58188491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680061804.XA Active CN108348582B (zh) | 2015-09-04 | 2016-09-02 | 用于使用胰高血糖素受体拮抗性抗体治疗心力衰竭的方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10765737B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3344279B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6890340B6 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108348582B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016318097B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2999747A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017040986A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7005638B2 (ja) | 2017-01-27 | 2022-02-04 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | グルカゴン受容体結合タンパク質及びその使用方法 |
| EP3829636A1 (en) | 2018-07-27 | 2021-06-09 | NGM Biopharmaceuticals, Inc. | Use of glucagon receptor antagonists with immunotherapeutic agent |
| JP7840511B2 (ja) | 2019-02-01 | 2026-04-06 | 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 | 抗クローディン18抗体及びそれらの使用の方法 |
| CN118393150B (zh) * | 2024-06-27 | 2024-09-13 | 潍坊市润生畜禽良种有限公司 | 一种优化gcgr卵黄抗体制备的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030103983A1 (en) | 2002-05-09 | 2003-06-05 | Pressler Milton Lethan | Ace inhibitor-vasopressin antagonist combinations |
| WO2006005469A2 (en) | 2004-07-15 | 2006-01-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr) |
| CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| US9034883B2 (en) * | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
-
2016
- 2016-09-02 CA CA2999747A patent/CA2999747A1/en active Pending
- 2016-09-02 WO PCT/US2016/050183 patent/WO2017040986A1/en not_active Ceased
- 2016-09-02 AU AU2016318097A patent/AU2016318097B2/en not_active Ceased
- 2016-09-02 EP EP16843103.9A patent/EP3344279B1/en active Active
- 2016-09-02 JP JP2018511277A patent/JP6890340B6/ja active Active
- 2016-09-02 CN CN201680061804.XA patent/CN108348582B/zh active Active
- 2016-09-02 US US15/757,352 patent/US10765737B2/en active Active
-
2020
- 2020-07-28 US US16/941,290 patent/US11446376B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 丁淑贞等.救治原则与方法.《心内科护理学》.2015,第26页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200353079A1 (en) | 2020-11-12 |
| US11446376B2 (en) | 2022-09-20 |
| JP2018528210A (ja) | 2018-09-27 |
| AU2016318097B2 (en) | 2023-04-20 |
| AU2016318097A1 (en) | 2018-04-12 |
| CA2999747A1 (en) | 2017-03-09 |
| WO2017040986A1 (en) | 2017-03-09 |
| EP3344279A1 (en) | 2018-07-11 |
| US20180256713A1 (en) | 2018-09-13 |
| US10765737B2 (en) | 2020-09-08 |
| CN108348582A (zh) | 2018-07-31 |
| JP6890340B2 (ja) | 2021-06-18 |
| JP6890340B6 (ja) | 2021-07-14 |
| EP3344279A4 (en) | 2019-03-27 |
| EP3344279B1 (en) | 2020-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110997726B (zh) | 治疗或预防内分泌fgf-关联疾病的组合物和方法 | |
| US11446376B2 (en) | Methods for treating heart failure using glucagon receptor antagonistic antibodies | |
| JP2022177158A (ja) | 心不全を処置するための組成物および方法 | |
| JP2020196750A (ja) | 線維症を処置するためのセニクリビロック併用療法 | |
| EP2951205B1 (en) | Anti-activin-a compounds for the treatment of ovarian cancer | |
| JP2021506297A (ja) | Wntサロゲート分子及びその使用 | |
| CN107614695B (zh) | 用胰高血糖素受体拮抗性抗体治疗肥胖症和非酒精性脂肪肝病或非酒精性脂肪性肝炎的方法 | |
| JP2019504064A (ja) | 抗プロ/潜在型ミオスタチン抗体およびその使用方法 | |
| TW202317175A (zh) | 用於重量管理及相關代謝病症之療法 | |
| JP7374765B2 (ja) | 抗dkk-1抗体を使用して癌を治療するためのバイオマーカーとしてのベータ-カテニンの使用 | |
| AU2020319899A1 (en) | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics | |
| JP2015502975A (ja) | ヒト成長ホルモン受容体アンタゴニスト抗体およびその使用方法 | |
| TW202319069A (zh) | 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法 | |
| CN112839672A (zh) | 用于减少脂蛋白a形成以及治疗主动脉瓣硬化和主动脉狭窄的组合物和方法 | |
| US20180244792A1 (en) | Anti-fibrotic effect of cd70 | |
| JP2023506450A (ja) | 拡張機能障害の防止及び治療のためのアミロイドベータ抗体又はワクチンを含む療法組成物 | |
| US20240025987A1 (en) | Use of anti-il-27 antibodies | |
| US20240166759A1 (en) | Combinations comprising anti-tm4sf1 antibodies and immunotherapeutic agents and methods of using the same | |
| WO2026101890A1 (en) | Combinations of anti-il-27 antibodies with toripalimab and bevacizumab | |
| CN115279393A (zh) | 以介白素24或介白素20拮抗剂治疗组织纤维化和/或损伤和/或器官衰竭 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |